Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients
Primary:

路To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer

Secondary:

路To evaluate the toxicity of the combination
Non Small Cell Lung Cancer
DRUG: oxaliplatine / gemcitabine / Vinorelbine
Objective rate of response (ORR) according to the RECIST criterion, as evaluated by a review panel of outside experts.
Progression free survival (PFS), Overall survival (OS)
Primary:

路To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer

Secondary:

路To evaluate the toxicity of the combination